MCL1 and diffuse large B-cell lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL) DOHH2 and SU-DHL-16 cells, which have high Mcl-1 protein levels and are resistant to ABT-199 [18], showed high sensitivity to dinaciclib + ABT-199 (Figure 6G, 6H), a combination that was highly synergistic (CI<0.2) (Figure 6J).